Schafer Cullen Capital Management’s Gilead Sciences GILD Stock Holding History

Schafer Cullen Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-3,970	Closed	-$305K	–	231
2020 Q2	$305K	Buy	+3,970	New	+$304K	﹤0.01%	192
2018 Q4	–	Sell	-4,010	Closed	-$310K	–	244
2018 Q3	$310K	Hold	4,010	–	–	﹤0.01%	205
2018 Q2	$284K	Hold	4,010	–	–	﹤0.01%	213
2018 Q1	$302K	Hold	4,010	–	–	﹤0.01%	222
2017 Q4	$287K	Hold	4,010	–	–	﹤0.01%	234
2017 Q3	$325K	Hold	4,010	–	–	﹤0.01%	230
2017 Q2	$284K	Buy	+4,010	New	+$267K	﹤0.01%	239

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Schafer Cullen Capital Management's GILD Position: Q3 2020 in Review

Schafer Cullen Capital Management sold out of Gilead Sciences (GILD) in Q3 2020, closing a stake of 3,970 shares — an estimated $305K sold.

Schafer Cullen Capital Management first reported a position in GILD in Q2 2017 and held it in 7 quarters. The position peaked at $325K in Q3 2017. 1,538 funds tracked by Wall St. Rank hold GILD as of Q3 2020.

Schafer Cullen Capital Management reported no remaining Gilead Sciences position as of Q3 2020 after selling out during the quarter.
Schafer Cullen Capital Management sold 3,970 Gilead Sciences shares in Q3 2020, an estimated $305K.
Schafer Cullen Capital Management first reported a position in Gilead Sciences in Q2 2017 and held it in 7 quarters.
Schafer Cullen Capital Management's Gilead Sciences position peaked at $325K in Q3 2017.
1,538 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2020.

Based on Schafer Cullen Capital Management's 13F filing for Q3 2020, filed 2 Nov 2020.